Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients. 1979

B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula

Absent response of serum thyrotrophin (TSH) after stimulation with 200 micrograms synthetic thyrotrophin-releasing hormone (TRH) was used as a criterion of adequate suppression of TSH in the treatment of thyroid carcinoma patients with thyroxine. The mean causing total suppression of the response was 223 micrograms of thyroxine per day. At this dose level about 40% of the patients had serum thyroxine concentrations above the upper reference interval and only 10% had elevated triiodothyronine concentrations. In some patients the TSH response to TRH varied between absent and low normal when tested at long intervals. The ideal dose of thyroxine is obviously slightly higher than the smallest one causing total suppression of the TSH response to TRH, i.e. about 250 micrograms a day. The individual dose must be found using the TRH stimulation test because serum thyroid hormone levels cannot be used as a guideline for adequate dosage. In some patients the thyroid remnant of apparently normal thyroid tissue was not totally suppressed although the thyroxine dose was definitely above the level causing suppression of the response to TRH.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm

Related Publications

B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
March 1994, Clinical endocrinology,
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
January 1994, European journal of cancer (Oxford, England : 1990),
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
July 2022, Clinical endocrinology,
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
January 1993, European journal of cancer (Oxford, England : 1990),
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
May 1976, The Journal of clinical endocrinology and metabolism,
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
September 1986, Clinical endocrinology,
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
July 2023, Endokrynologia Polska,
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
April 1987, Presse medicale (Paris, France : 1983),
B A Lamberg, and M Rantanen, and P Saarinen, and K Liewendahl, and A Sivula
January 2017, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!